Xospata(gilteritinib)
Xospata (gilteritinib) is a small molecule pharmaceutical. Gilteritinib was first approved as Xospata on 2018-11-28. It is used to treat myeloid leukemia acute in the USA. It has been approved in Europe to treat myeloid leukemia acute. It is known to target tyrosine-protein kinase receptor UFO, high affinity nerve growth factor receptor, proto-oncogene tyrosine-protein kinase receptor Ret, tyrosine-protein kinase Mer, leukocyte tyrosine kinase receptor, proto-oncogene tyrosine-protein kinase ROS, receptor-type tyrosine-protein kinase FLT3, and ALK tyrosine kinase receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
Trade Name
FDA
EMA
Xospata
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Gilteritinib fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| XOSPATA | Astellas Pharma | N-211349 RX | 2018-11-28 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| xospata | New Drug Application | 2022-04-29 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| myeloid leukemia acute | — | D015470 | C92.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
GILTERITINIB FUMARATE, XOSPATA, ASTELLAS | |||
| 2025-11-28 | ODE-222 | ||
HCPCS
No data
Clinical
Clinical Trials
60 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | — | C92.0 | 26 | 21 | 6 | — | 8 | 48 |
| Leukemia | D007938 | — | C95 | 24 | 16 | 5 | — | 7 | 41 |
| Myeloid leukemia | D007951 | — | C92 | 24 | 16 | 5 | — | 6 | 40 |
| Myelodysplastic syndromes | D009190 | — | D46 | 3 | 4 | 1 | — | — | 6 |
| Preleukemia | D011289 | — | — | 2 | 2 | 1 | — | — | 4 |
| Syndrome | D013577 | — | — | 2 | 2 | 1 | — | — | 4 |
| Refractory anemia with excess of blasts | D000754 | — | D46.2 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 4 | 2 | — | — | — | 4 |
| Recurrence | D012008 | — | — | 1 | 3 | — | — | — | 3 |
| Hematologic neoplasms | D019337 | — | — | 2 | 1 | — | — | 1 | 3 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 2 | 2 | — | — | — | 2 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 2 | 2 | — | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 1 | — | — | — | 2 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | 1 | — | — | — | 2 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | 1 | — | — | — | 1 |
| Myelomonocytic leukemia acute | D015479 | — | C92.5 | 1 | 1 | — | — | — | 1 |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | — | 1 | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Neoplasms by histologic type | D009370 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Residual neoplasm | D018365 | — | — | — | — | — | — | 2 | 2 |
| Pathologic complete response | D000095384 | — | — | — | — | — | — | 2 | 2 |
| Frailty | D000073496 | — | R53.1 | — | — | — | — | 1 | 1 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Gilteritinib |
| INN | gilteritinib |
| Description | Gilteritinib is a member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation. It has a role as an apoptosis inducer, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor and an antineoplastic agent. It is a N-methylpiperazine, a member of piperidines, a secondary amino compound, a monomethoxybenzene, a member of pyrazines, a primary carboxamide, an aromatic amine and a member of oxanes. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1 |
Identifiers
| PDB | — |
| CAS-ID | 1254053-43-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3301622 |
| ChEBI ID | — |
| PubChem CID | 49803313 |
| DrugBank | DB12141 |
| UNII ID | 66D92MGC8M (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
RET
RET
Organism
Homo sapiens
Gene name
RET
Gene synonyms
CDHF12, CDHR16, PTC, RET51
NCBI Gene ID
Protein name
proto-oncogene tyrosine-protein kinase receptor Ret
Protein synonyms
Cadherin family member 12, cadherin-related family member 16, Proto-oncogene c-Ret, rearranged during transfection, ret proto-oncogene (multiple endocrine neoplasia and medullary thyroid carcinoma 1, Hirschsprung disease), RET receptor tyrosine kinase
Uniprot ID
Mouse ortholog
Ret (19713)
proto-oncogene tyrosine-protein kinase receptor Ret (P35546)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,884 documents
View more details
Safety
Black-box Warning
Black-box warning for: Xospata
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,934 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use